The pharmacokinetic and pharmacodynamic properties of the second-generation basal insulin glargine 300 Units/mL (Gla-300) may be of benefit in the treatment of type 1 diabetes mellitus (T1DM). Gla-300 provides a stable and sustained time-action profile, which is associated with glycaemic control and flexible dosing schedule. This review summarises the available evidence on the safety and efficacy of Gla-300 in children and adolescents with T1DM. Gla-300 is as effective as the first-generation basal insulin glargine 100 Units/mL (Gla-100), a standard of care for patients with diabetes in reducing HbA1c, and shows a lower risk of severe hypoglycaemia and hyperglycaemia in children and adolescents with T1DM. However, Gla-300 and Gla-100 are not bioequivalent and are not directly interchangeable. Real-world studies on patients aged 6–17 years are limited. To date, only one small study assessed the effectiveness and safety of Gla-300 versus Gla-100 in newly diagnosed T1DM paediatric patients, confirming the treatment safety and effectiveness of Gla-300 in clinical practice. Gla-300 is a longer-acting basal insulin alternative in the management of children (aged ≥ 6 years) and adolescents with T1DM.

第二代基础甘精胰岛素300单位/mL（Gla-300）的药代动力学和药效学特性可能对治疗1型糖尿病（T1DM）有益。Gla-300 提供稳定且持续的时间作用曲线，与血糖控制和灵活的给药方案相关。本综述总结了 Gla-300 在儿童和青少年 T1DM 中的安全性和有效性的现有证据。Gla-300 与第一代基础甘精胰岛素 100 Units/mL (Gla-100) 一样有效，后者是糖尿病患者降低 HbA1c 的护理标准，并显示儿童和青少年发生严重低血糖和高血糖的风险较低与 T1DM。但是，Gla-300 和 Gla-100 不是生物等效的，也不能直接互换。对 6-17 岁患者的真实世界研究是有限的。迄今为止，只有一项小型研究评估了 Gla-300 与 Gla-100 在新诊断的 T1DM 儿科患者中的有效性和安全性，证实了 Gla-300 在临床实践中的治疗安全性和有效性。Gla-300 是一种长效基础胰岛素替代品，用于治疗患有 T1DM 的儿童（≥ 6 岁）和青少年。